Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Compromise FDA Reform Bill Passes House, Adds $225 Million In User Fees For Drug Safety

This article was originally published in The Pink Sheet Daily

Executive Summary

Legislation requires patient summary of clinical trial results, but only if it can be written without being promotional.

You may also be interested in...



Strange Bedfellows: Regulators May Revive Biotech Deals And IPOs

Still mourning the loss of IPOs and desperate for exits, biotechs could be forgiven for being pessimistic. But some experts say health reform and other new regulations will renew the value of innovative drugs and revive the crucial public markets

Strange Bedfellows: Regulators May Revive Biotech Deals And IPOs

Still mourning the loss of IPOs and desperate for exits, biotechs could be forgiven for being pessimistic. But some experts say health reform and other new regulations will renew the value of innovative drugs and revive the crucial public markets

FDA Reform Bill Could Still Face Administrative Gauntlet After Enactment

Implementation of new FDA drug safety authorities may not be quick or easy if lengthy rule-making is a prerequisite to action.

Related Content

Topics

UsernamePublicRestriction

Register

PS066624

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel